AF
EWTX icon

Allworth Financial’s Edgewise Therapeutics EWTX Stock Holding History

Allworth Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.65K Buy
84
+28
+50% +$807 ﹤0.01% 4253
2025
Q4 		$1.39K Buy
56
+23
+70% +$462 ﹤0.01% 4254
2025
Q3 		$536 Buy
+33
New +$468 ﹤0.01% 4417
2024
Q3 		– Sell
-45
Closed -$962 – 3772
2024
Q2 		$962 Hold
45
– – ﹤0.01% 3178
2024
Q1 		$821 Hold
45
– – ﹤0.01% 3144
2023
Q4 		$493 Buy
+45
New +$316 ﹤0.01% 3130
2023
Q3 		– Sell
-221
Closed -$1.71K – 3472
2023
Q2 		$1.71K Buy
+221
New +$1.86K ﹤0.01% 2542

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Allworth Financial's EWTX Position: Q1 2026 in Review

Allworth Financial increased its Edgewise Therapeutics (EWTX) stake by 50% in Q1 2026, buying an estimated $807 and bringing the position to 84 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #4253.

Allworth Financial first reported a position in EWTX in Q2 2023 and has held it in 7 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Allworth Financial held 84 shares of Edgewise Therapeutics worth $2.65K as of Q1 2026.
  • Allworth Financial bought 28 Edgewise Therapeutics shares in Q1 2026, an estimated $807.
  • Edgewise Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4253 holding.
  • Allworth Financial first reported a position in Edgewise Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.